Chongqing Taiji Industry

What Chongqing Taiji Industry does

Chongqing Taiji Industry (太极集团), publicly listed on the Shanghai Stock Exchange (SSE: 600129), is a Chongqing-headquartered traditional Chinese medicine (TCM) pharmaceutical conglomerate founded in 1900. The group operates through 13 production factories and employs more than 10,000 people, holding 1,240 drug approvals across five therapeutic product lines: Digestive/Metabolic, Respiratory/Antibiotics, Cardiovascular/Cerebrovascular, Anesthetic/Oncology, and Big Health. Flagship brands include Taiji Huoxiang Zhengqi Oral Liquid (太极藿香正气口服液), Taiji Jizhi Syrup (太极急支糖浆), and Taiji Tongtian Oral Liquid (太极通天口服液), supplemented by the premium Taiji Shangcao (太极上草) herbal sub-brand. The company holds two China time-honored brand designations and one national-level intangible cultural heritage recognition, and operates wholly-owned subsidiaries including Chongqing Fuling Pharmaceutical Factory, Southwest Pharmaceutical, Chongqing Tongjunge Pharmaceutical Factory, and Zhejiang Dongfang Pharmaceutical (acquired June 2000).

The group's revenue model centers on manufacturing and selling TCM pharmaceutical products through an established national sales network, with primary end-customers being mass-market healthcare consumers purchasing OTC products for digestive, respiratory, cardiovascular, and general wellness needs. Distribution is supported by an integrated subsidiary ecosystem and the company's affiliation with Sinopharm (China National Pharmaceutical Group). Go-to-market is sales-led, leveraging the group's national sales network plus on-site technical support teams to expand acquired subsidiaries. Marketing channels include company news media, branded campaigns (such as the 'Guoyao Taiji' themed metro train launch in Changsha), and an active investor relations program.

Recent financial performance shows a significant revenue contraction: disclosed revenue declined from approximately $15.6B in 2023 to $10.5B in 2025, with net income collapsing from $822M (2023) to $26.7M (2024) before partially recovering to $120.6M in 2025. The company has framed 2025 as a 'destocking and strong sales' phase and is investing in scientific validation (publication in top journal CHM, IF=11.2), regulatory moat-building (intangible cultural heritage designation), and consumer-facing brand campaigns to drive a marketing-led re-acceleration.

Name

Chongqing Taiji Industry

Legal name

太极集团有限公司

Website

http://www.taiji.com/

Company type

Public

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Chongqing Taiji Industry is a publicly listed (SSE: 600129) traditional Chinese medicine pharmaceutical conglomerate operating 13 factories and 1,240 drug approvals across digestive, respiratory, cardiovascular, oncology, and consumer health lines, serving mass-market healthcare consumers in China via a national sales network under Sinopharm affiliation.

Ownership category

akta.pro rank

Product category

Traditional Chinese Medicine Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD), Vitamins & Minerals (Single Nutrients) (CRADAGAB)

Keywords

• Traditional Chinese medicine
• Pharmaceutical manufacturing
• Herbal medicine products
• TCM oral liquid
• Consumer health supplements

Headquarters

HQ city

Chongqing

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Products Sales: Core revenue from manufacturing and selling traditional Chinese medicine products including digestive metabolism, respiratory antibiotics, cardiovascular, anesthetic oncology, and grand health product lines through established sales networks

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Chongqing Taiji Industry manufactures and sells traditional Chinese medicine (TCM) pharmaceutical and consumer health products across five therapeutic lines: Digestive/Metabolic (anchored by Taiji Huoxiang Zhengqi Oral Liquid), Respiratory/Antibiotics (anchored by Taiji Jizhi Syrup), Cardiovascular/Cerebrovascular (anchored by Taiji Tongtian Oral Liquid), Anesthetic/Oncology, and the Big Health line (anchored by the Taiji Shangcao premium herbal sub-brand). Products are distributed through the group's national sales network and 13 production factories under wholly-owned subsidiaries, including Chongqing Fuling Pharmaceutical Factory, Southwest Pharmaceutical, Chongqing Tongjunge Pharmaceutical Factory, and Zhejiang Dongfang Pharmaceutical.

Product overview

Chongqing Taiji Industry (太极集团) operates as a comprehensive pharmaceutical conglomerate offering traditional Chinese medicine and chemical pharmaceutical products. The portfolio consists of five major product lines: Digestive/Metabolic Series (消化代谢系列), Respiratory/Antibiotics Series (呼吸抗生素系列), Cardiovascular/Cerebrovascular Series (心脑血管系列), Anesthetic/Oncology Series (麻精肿瘤系列), and Big Health Series (大健康系列). Key flagship products include 太极藿香正气口服液 for digestive disorders, 太极急支糖浆 for respiratory conditions, and 太极通天口服液 for cardiovascular issues. The company also produces the 太极上草 premium herbal sub-brand. With 1,240 drug approvals, 13 production factories, and over 10,000 employees, the group has 2 China time-honored brands and 1 national intangible cultural heritage designation.

Differentiator

Problem solved

Functional benefit

Brands

• 太极藿香正气口服液: Digestive and metabolic product line - 解表化湿 理气和中 (Releases exterior, transforms dampness, regulates qi, harmonizes middle)
• 太极急支糖浆
• 太极通天口服液
• 麻精肿瘤系列
• 太极上草

Products and services

• Taiji Huoxiang Zhengqi Oral Liquid (太极藿香正气口服液) Traditional Chinese medicine oral liquid for relieving external colds, transforming dampness, regulating qi, and harmonizing the middle jiao. Used for symptoms such as headache, chest tightness, and abdominal distension. Anchors the Digestive/Metabolic product line.
• Taiji Jizhi Syrup (太极急支糖浆) Syrup formulation for clearing heat, resolving phlegm, diffusing lung, and stopping cough. Used for acute bronchitis and other respiratory conditions. Anchors the Respiratory/Antibiotics product line.
• Taiji Tongtian Oral Liquid (太极通天口服液) Oral liquid for invigorating blood, transforming stasis, dispelling wind, and relieving pain. Used for cardiovascular and cerebrovascular conditions. Anchors the Cardiovascular/Cerebrovascular product line.
• Anesthetic/Oncology Series (麻精肿瘤系列) Product line focused on anesthetic and oncology medications, supporting collaborative development toward a pain-free world.
• Taiji Shangcao (太极上草) Premium Herbal Sub-brand Premium herbal product line under the Big Health category, featuring quality seed sources, good ecological environment, and zero heavy metal exceedance standards. Targets health-conscious consumers seeking premium wellness products.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core, supporting and flagship.

• Zhejiang Dongfang Pharmaceutical (浙江东方制药)coreStrategic or Co-development PartnerTaiji Group acquired Zhejiang Dongfang Pharmaceutical (originally Shaoxing Traditional Chinese Medicine Factory) in June 2000. The subsidiary has been supported with national market expansion through Taiji's sales network and technical teams for on-site assistance. Zhejiang Dongfang Pharmaceutical has facilitated Taiji's green transformation by connecting the group with advanced pharmaceutical equipment manufacturers in Wenzhou and Hangzhou.
• Advanced pharmaceutical equipment manufacturers in Wenzhou and HangzhousupportingTechnology or IntegrationEquipment manufacturers identified through Zhejiang Dongfang Pharmaceutical connection, enabling Taiji Group's green transformation and modernization of pharmaceutical production capabilities
• China National Pharmaceutical Group Co., Ltd. (中国医药集团有限公司)flagshipOthersParent company of Taiji Group, part of Sinopharm (国药集团). Listed as key partner in company website links section, representing the group's position within China's largest pharmaceutical state-owned enterprise.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Yunnan Baiyao Group: Major Chinese TCM and pharmaceutical conglomerate with similar diversified product portfolio across TCM and Western medicine. Comparable scale, public listing, and Chinese state-affiliated structure make it a direct peer.
• China Resources Sanjiu Medical & Pharmaceutical: Large Chinese TCM manufacturer under China Resources group with OTC and prescription TCM products. Comparable portfolio breadth across respiratory, digestive, and cardiovascular TCM categories and similar state-affiliated backing.
• Beijing Tongrentang: Historic Chinese TCM manufacturer with similar century-old heritage, China time-honored brand status, and broad TCM product portfolio. Direct competitor in the heritage TCM segment targeting similar consumer health needs.
• Guangzhou Pharmaceutical Holdings (GPHL): Large Chinese state-affiliated pharmaceutical conglomerate with broad TCM and chemical drug portfolio, including Wanglaoji herbal tea brand. Comparable scale, diversified therapeutic focus, and exposure to traditional Chinese medicine category.
• Pien Tze Huang (Zhangzhou Pien Tze Huang Pharmaceutical): Heritage Chinese TCM manufacturer focused on specialty TCM formulations. Comparable as a state-affiliated, publicly listed TCM pure-play targeting similar consumer health and specialty therapeutic segments.
• China Traditional Chinese Medicine Holdings (Sinopharm TCM): Sinopharm-affiliated TCM holding company focused on traditional Chinese medicine manufacturing and distribution. Closely comparable TCM focus, parent group affiliation, and product portfolio scope across major therapeutic areas.

Broad incumbents

• Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical conglomerates spanning distribution, manufacturing, and retail pharmacy. Overlaps with Taiji in TCM and chemical pharma manufacturing, but operates at significantly larger scale across more therapeutic areas.
• China National Pharmaceutical Group (Sinopharm): Parent affiliate and China's largest state-owned pharmaceutical group. Provides distribution and scale to Taiji and competes across the broader Chinese pharmaceutical value chain including TCM, Western medicine, and medical devices.
• Jiangsu Hengrui Pharmaceuticals: China's largest innovative pharmaceutical company with broad prescription drug portfolio across oncology, anesthesia, and cardiovascular. Comparable scale, public listing, and exposure to cardiovascular and anesthetic product lines overlapping with Taiji's portfolio.

Regional players

• Zhejiang Huahai Pharmaceutical: Major Chinese pharmaceutical manufacturer based in Zhejiang with focus on cardiovascular and specialty generics. Regional peer in Zhejiang province (where Taiji's subsidiary Zhejiang Dongfang Pharmaceutical operates) and overlapping cardiovascular product focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chongqing Taiji Industry